Print

Active Biotech to Present at the Rodman & Renshaw 4th Annual Global Healthcare Conference

2007-05-10

The presentation will include an update on the following drugs: laquinimod, the company's oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd; ANYARA, Active Biotech's novel concept for the treatment of primarily renal cancer; and other key projects in clinical development, such as TASQ, for prostate cancer; 57-57, for Lupus (SLE); and RhuDex® (licensed to MediGene AG) for rheumatoid arthritis.
The Active Biotech audio and slide presentation will be web cast live on 15 May, at
10:05 AM CEST. A replay will be available approximately two hours following the presentation and archived on the company's web site. To access the live and replay presentations, visit the Active Biotech web site - www.activebiotech.com.
The complete Conference Schedule can be accessed at: www.rodmanandrenshaw.com/eu07conference
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is conducted in cooperation with Chelsea Therapeutics.
Contacts:
Active Biotech AB
Cecilia Hofvander
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Direct: +46 (0)46 19 11 22
Fax: +46 (0)46-19 20 50
www.activebiotech.com
pdf



Back